Adipocytokines As Predictors of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Development in Type 2 Diabetes Mellitus Patients

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2024 Mar 8

PMID 38455340

Authors

Almir Fajkic

Rijad Jahic

Almira Hadzovic-Dzuvo

Orhan Lepara

Affiliations

Soon will be listed here.

Abstract

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common chronic liver condition. Due to pathophysiological processes, MASLD's relation to type 2 diabetes mellitus (T2DM) is still unclear, especially when the role of adipocytokines is taken into consideration.

Objective: This study aims to examine the potential predictive value of adiponectin and resistin for MASLD in T2DM.

Patients And Methods: In a two-year study, 71 T2DM patients were categorized into MASLD-T2DM and non-MASLD-T2DM groups according to MASLD development. Serum samples were tested for resistin, adiponectin, high-density lipoprotein cholesterol, fasting glucose, and triglycerides. An appropriate equation is used to calculate the adiponectin/resistin (A/R) index. The optimal cut-off values for differentiating MASLD patients from non-MASLD patients were determined using receiver operating characteristic (ROC) curves and the corresponding areas under the curve (AUC). To predict the onset of MASLD in patients with T2DM, a logistic regression analysis was performed.

Results: There were significant differences in adiponectin (p<0.001), resistin (p<0.001), and A/R index (p<0.001) between T2DM individuals with and without MASLD. The ROC curve for resistin produced an AUC of 0.997 (p<0.001) with a sensitivity of 96.1% and a specificity of 100% for the cut-off point of 253.15. Adiponectin (OR, 0.054; 95% CI, 0.011-0.268; p<0.001) and resistin (OR, 1.745; 95% CI, 1.195-2,548; p=0.004) were found to be independent predictors for MASLD by logistic regression analysis.

Conclusion: This study confirms the potential of adiponectin and resistin as predictors of MASLD development in T2DM.

Citing Articles

Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment.

Byrne C, Armandi A, Pellegrinelli V, Vidal-Puig A, Bugianesi E Nat Rev Gastroenterol Hepatol. 2025; .

PMID: 39962331 DOI: 10.1038/s41575-025-01045-z.

Adiponectin and Adiponectin Receptors in Atherosclerosis.

Gianopoulos I, Mantzoros C, Daskalopoulou S Endocr Rev. 2024; 46(1):1-25.

PMID: 39106421 PMC: 11720176. DOI: 10.1210/endrev/bnae021.

References

Habib S, Al-Khlaiwi T, Butt M, Habib S, Al-Khliwi H, Al-Regaiey K . Novel Adiponectin-Resistin Indices and Ratios Predict Increased Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus. J Saudi Heart Assoc. 2023; 35(1):59-65. PMC: 10229130. DOI: 10.37616/2212-5043.1332. View

Forlano R, Stanic T, Jayawardana S, Mullish B, Yee M, Mossialos E . A prospective study on the prevalence of MASLD in people with type-2 diabetes in the community. Cost effectiveness of screening strategies. Liver Int. 2023; 44(1):61-71. DOI: 10.1111/liv.15730. View

Gross B, Pawlak M, Lefebvre P, Staels B . PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. Nat Rev Endocrinol. 2016; 13(1):36-49. DOI: 10.1038/nrendo.2016.135. View

Pan J, Ding Y, Sun Y, Li Q, Wei T, Gu Y . Associations between Adipokines and Metabolic Dysfunction-Associated Fatty Liver Disease Using Three Different Diagnostic Criteria. J Clin Med. 2023; 12(6). PMC: 10051925. DOI: 10.3390/jcm12062126. View

Vasiliauskaite-Brooks I, Sounier R, Rochaix P, Bellot G, Fortier M, Hoh F . Structural insights into adiponectin receptors suggest ceramidase activity. Nature. 2017; 544(7648):120-123. PMC: 5595237. DOI: 10.1038/nature21714. View

Yang G, Li L, Fang C, Zhang L, Li Q, Tang Y . Effects of free fatty acids on plasma resistin and insulin resistance in awake rats. Metabolism. 2005; 54(9):1142-6. DOI: 10.1016/j.metabol.2005.03.020. View

Marques V, Afonso M, Bierig N, Duarte-Ramos F, Santos-Laso A, Jimenez-Aguero R . Adiponectin, Leptin, and IGF-1 Are Useful Diagnostic and Stratification Biomarkers of NAFLD. Front Med (Lausanne). 2021; 8:683250. PMC: 8260936. DOI: 10.3389/fmed.2021.683250. View

Zhong S, Zhao L, Wang Y, Zhang C, Liu J, Wang P . Cluster of Differentiation 36 Deficiency Aggravates Macrophage Infiltration and Hepatic Inflammation by Upregulating Monocyte Chemotactic Protein-1 Expression of Hepatocytes Through Histone Deacetylase 2-Dependent Pathway. Antioxid Redox Signal. 2016; 27(4):201-214. DOI: 10.1089/ars.2016.6808. View

Liu Q, Zhao G, Li Q, Wu W, Zhang Y, Bian H . A comparison of NAFLD and MAFLD diagnostic criteria in contemporary urban healthy adults in China: a cross-sectional study. BMC Gastroenterol. 2022; 22(1):471. PMC: 9675196. DOI: 10.1186/s12876-022-02576-4. View

10.

van Son K, Te Nijenhuis-Noort L, Boone S, Mook-Kanamori D, Holleboom A, Roos P . Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in a middle-aged population with overweight and normal liver enzymes, and diagnostic accuracy of noninvasive proxies. Medicine (Baltimore). 2024; 103(1):e34934. PMC: 10766322. DOI: 10.1097/MD.0000000000034934. View

11.

Estes C, Razavi H, Loomba R, Younossi Z, Sanyal A . Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2017; 67(1):123-133. PMC: 5767767. DOI: 10.1002/hep.29466. View

12.

Herath H, Weerasinghe N, Weerarathna T, Amarathunga A . A Comparison of the Prevalence of the Metabolic Syndrome among Sri Lankan Patients with Type 2 Diabetes Mellitus Using WHO, NCEP-ATP III, and IDF Definitions. Int J Chronic Dis. 2018; 2018:7813537. PMC: 6106798. DOI: 10.1155/2018/7813537. View

13.

Bozic D, Podrug K, Mikolasevic I, Grgurevic I . Ultrasound Methods for the Assessment of Liver Steatosis: A Critical Appraisal. Diagnostics (Basel). 2022; 12(10). PMC: 9600709. DOI: 10.3390/diagnostics12102287. View

14.

Boutari C, Tziomalos K, Athyros V . The adipokines in the pathogenesis and treatment of nonalcoholic fatty liver disease. Hippokratia. 2018; 20(4):259-263. PMC: 5788238. View

15.

Chen Z, Yu R, Xiong Y, Du F, Zhu S . A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease. Lipids Health Dis. 2017; 16(1):203. PMC: 5644081. DOI: 10.1186/s12944-017-0572-9. View

16.

Hagstrom H, Vessby J, Ekstedt M, Shang Y . 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J Hepatol. 2023; 80(2):e76-e77. DOI: 10.1016/j.jhep.2023.08.026. View

17.

Han D, Chen J, Liu S, Zhang Z, Zhao Z, Jin W . Serum Resistin Levels in Adult Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. J Clin Transl Hepatol. 2021; 9(4):484-493. PMC: 8369026. DOI: 10.14218/JCTH.2021.00018. View

18.

Kim H, Lee D, An T, Park H, Kim W, Bae K . Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC. Int J Mol Sci. 2021; 22(9). PMC: 8123490. DOI: 10.3390/ijms22094495. View

19.

Chan W, Chuah K, Rajaram R, Lim L, Ratnasingam J, Vethakkan S . Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review. J Obes Metab Syndr. 2023; 32(3):197-213. PMC: 10583766. DOI: 10.7570/jomes23052. View

20.

Xu W, Yu L, Zhou W, Luo M . Resistin increases lipid accumulation and CD36 expression in human macrophages. Biochem Biophys Res Commun. 2006; 351(2):376-82. DOI: 10.1016/j.bbrc.2006.10.051. View